-
Drug, Healthcare and Patient Safety
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital
Original Research
(3332) Views (529) Full article downloads
Authors: Rajakannan Thiyagu, Surulivel R Mallayasamy, Valakkathala Rajesh, et al
Published Date June 2010
Volume 2010:2 Pages 95 - 100
DOI: http://dx.doi.org/10.2147/DHPS.S11222
Rajakannan Thiyagu1, Surulivel R Mallayasamy1, Valakkathala Rajesh1, Varma Muralidhar2, Prabhu Smitha3, Vidyasagar Sudha2, Bairy K Laxminarayana4
1Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India; 2Department of General Medicine, 3Department of Skin & STD, 4Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, India
Objective: Adverse drug events (ADEs) are drug-related events which continue to pose serious challenges to the safety of patients. There are a number of ways to monitor ADEs, and the use of indictors to screen them provides an alternative method for detecting them. This method helps to assess the safety of drugs by the manual record review technique. The aim of this work was to develop a list of indicators to use in medical units of the study hospital to identify ADEs.
Setting: Tertiary care teaching hospital in India.
Method: An initial list of ADE indicators based on published literature was developed by a panel of three experts. The list of indicators was subjected to review by a Delphi panel of five members. The Delphi panel reviewed the list of valid indicators and also suggested an addition of new indicators. The final list of indicators was used to review 100 previously documented ADE case reports. The case reports were screened for the presence of any of the indicators from the list. Parameters studied included number of indicators per case report and the most used indicators.
Results: From the literature, a 72 item indicator list was initially prepared which was further narrowed down to a list of 63 items. The Delphi panel conducted a review with these 63 items. At the end of review, and after addition and deletion of indicators, a 49 item indicator list was finalized. When this list of indicators was used for the review of ADE case reports, 42 indicators were identified. On average, three indicators were present in the reviewed case reports.
Conclusion: An indicator list was developed for identification of ADEs in the study setup. The relevance of this indicator list was demonstrated by the presence of these indicators in the previously documented ADE reports. This is the first study from India to report on the development of ADE indicators, which might provide an alternative method to detecting ADEs in the setup of future studies.
Keywords: adverse drug events, drug safety indicators, Delphi panel
Readers of this article also read:
A review and empirical study of the composite scales of the Das–Naglieri cognitive assessment system
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Pharmacist-documented interventions during the dispensing process in a primary health care facility in Qatar
Identification and reduction of adverse drug reactions
Erratum
Erratum
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies
Analysis on descriptions of precautionary statements in package inserts of medicines
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




